Provided by Tiger Fintech (Singapore) Pte. Ltd.

Madrigal Pharmaceuticals

294.64
-4.9300-1.65%
Post-market: 294.640.00000.00%16:29 EDT
Volume:305.94K
Turnover:90.80M
Market Cap:6.54B
PE:-16.40
High:307.49
Open:300.11
Low:291.16
Close:299.57
Loading ...

BRIEF-Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis

Reuters
·
10 May

Madrigal Pharmaceuticals Inc - Patients Achieved 6.7 Kpa Reduction in Liver Stiffness

THOMSON REUTERS
·
10 May

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (Resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients With Compensated Mash Cirrhosis

THOMSON REUTERS
·
10 May

Madrigal Pharmaceuticals Inc - Rezdiffra Well-Tolerated With Low Discontinuation Rate

THOMSON REUTERS
·
10 May

Madrigal Pharmaceuticals: 65% of Patients With Clinically Significant Portal Hypertension at Baseline Moved Into Lower Risk Categories by Year Two

THOMSON REUTERS
·
10 May

Madrigal Pharmaceuticals Is Maintained at Buy by UBS

Dow Jones
·
03 May

Madrigal Pharmaceuticals Price Target Raised to $460.00/Share From $422.00 by B. Riley Securities

Dow Jones
·
03 May

Madrigal Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
02 May

UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating

MT Newswires Live
·
02 May

Madrigal Pharmaceuticals Reports Strong Q1 2025 Results

TIPRANKS
·
02 May

Q1 2025 Madrigal Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
02 May

Madrigal Pharmaceuticals: Strong Financial Performance and Strategic Positioning Justify Buy Rating

TIPRANKS
·
02 May

Stock Track | Madrigal Pharmaceuticals Plummets 5.59% Despite Beating Q1 Earnings Estimates

Stock Track
·
01 May

Madrigal Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
01 May

Madrigal Pharmaceuticals Q1 Loss Narrows

MT Newswires Live
·
01 May

Madrigal: Q1 Earnings Snapshot

Associated Press Finance
·
01 May

Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q1 Revenue $137.3M, vs. FactSet Est of $114.7M

MT Newswires Live
·
01 May

Madrigal Pharmaceuticals Reports Q1 2025: Rezdiffra Sales Reach $137.3M; Positive Feedback from Healthcare Providers

Reuters
·
01 May

Madrigal Pharmaceuticals Q1 EPS $(3.32) Beats $(3.61) Estimate, Sales $137.25M Beat $113.76M Estimate

Benzinga
·
01 May

BRIEF-Madrigal Pharmaceuticals Q1 EPS USD -3.32

Reuters
·
01 May